Ocular Therapeutix Management
Management criteria checks 1/4
Ocular Therapeutix's CEO is Pravin Dugel, appointed in Apr 2024, has a tenure of 1.08 years. total yearly compensation is $18.65M, comprised of 2.5% salary and 97.5% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $1.44M. The average tenure of the management team and the board of directors is 1.3 years and 5.9 years respectively.
Key information
Pravin Dugel
Chief executive officer
US$18.7m
Total compensation
| CEO salary percentage | 2.5% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates
May 07
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S
Mar 25
FDA Approval And Adjusted Trials Will Expand Treatment Options
Mar 24 AXPAXLI's FDA amendment enables better dosing schedules, boosting market penetration and revenue through superior treatment durability.Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Mar 06Does Ocular Therapeutix (NASDAQ:OCUL) Have A Healthy Balance Sheet?
Feb 25Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$193m |
| Dec 31 2024 | US$19m | US$465k | -US$194m |
Compensation vs Market: Pravin's total compensation ($USD18.65M) is above average for companies of similar size in the US market ($USD4.04M).
Compensation vs Earnings: Insufficient data to compare Pravin's compensation with company performance.
CEO
Pravin Dugel (60 yo)
1.1yrs
Tenure
US$18,653,801
Compensation
Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 21, 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.1yrs | US$18.65m | 0.13% $ 1.4m | |
| Chief Scientific Officer | 1.3yrs | US$6.67m | 0.044% $ 498.8k | |
| Chief Development Officer | 2.9yrs | US$6.69m | 0.018% $ 205.2k | |
| CFO, COO & Principal Accounting Officer | 7.7yrs | US$1.34m | 0.077% $ 881.1k | |
| Chief Technical Officer | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | no data | no data | no data | |
| Vice President of Global Sales & Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 1.3yrs | no data | no data | |
| Chief Commercial Officer | 2.3yrs | no data | no data | |
| Chief Strategy Officer | 1.3yrs | no data | 0.075% $ 853.6k | |
| Chief Medical Officer | no data | no data | no data |
1.3yrs
Average Tenure
57yo
Average Age
Experienced Management: OCUL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.3yrs | US$18.65m | 0.13% $ 1.4m | |
| Lead Independent Director | 17.3yrs | US$406.31k | 0.038% $ 433.9k | |
| Independent Director | 3.7yrs | US$366.31k | 0.013% $ 150.2k | |
| Independent Director | 12.5yrs | US$363.81k | 0.095% $ 1.1m | |
| Independent Director | 1.8yrs | US$351.31k | 0.0050% $ 57.4k | |
| Independent Director | 6.2yrs | US$363.81k | 0.016% $ 182.5k | |
| Independent Director | 5.9yrs | US$351.31k | 0.013% $ 150.2k |
5.9yrs
Average Tenure
66yo
Average Age
Experienced Board: OCUL's board of directors are considered experienced (5.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 16:32 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocular Therapeutix, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Anita Dushyanth | Berenberg |
| Tazeen Ahmad | BofA Global Research |